Towards Precision Medicine in Psychosis

Benefits and Challenges of Multimodal Multicenter Studies-PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice

Tognin, Stefania; van Hell, Hendrika H; Merritt, Kate; Winter-van Rossum, Inge; Bossong, Matthijs G; Kempton, Matthew J; Modinos, Gemma; Fusar-Poli, Paolo; Mechelli, Andrea; Dazzan, Paola; Maat, Aija; de Haan, Lieuwe; Crespo-Facorro, Benedicto; Glenthøj, Birte; Lawrie, Stephen M; McDonald, Colm; Gruber, Oliver; van Amelsvoort, Therese; Arango, Celso; Kircher, Tilo; Nelson, Barnaby; Galderisi, Silvana; Bressan, Rodrigo; Kwon, Jun S; Weiser, Mark; Mizrahi, Romina; Sachs, Gabriele; Maatz, Anke; Kahn, René; McGuire, Phillip; PSYSCAN Consortium

Published in:
Schizophrenia Bulletin

DOI:
10.1093/schbul/sbz067

Publication date:
2020

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Tognin, S., van Hell, H. H., Merritt, K., Winter-van Rossum, I., Bossong, M. G., Kempton, M. J., ... PSYSCAN Consortium (2020). Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies-PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. Schizophrenia Bulletin, 46(2), 432-441. https://doi.org/10.1093/schbul/sbz067
Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice

Stefania Tognin1,2,3†, Hendrika H. van Hell*1,3,†, Kate Merritt†, Inge Winter-van Rossum3, Matthijs G. Bossong3, Matthew J. Kempton1, Gemma Modinos1, Paolo Fusar-Poli1,4,5, Andrea Mechelli1,3, Paola Dazzan1, Arija Maat1, Lieuewe de Haan1, Benedetto Crespo-Facorro1,4,6, Birte Glenthoj1,2,6, Stephen M. Lawrie12, Colm McDonald13, Oliver Gruber14, Therese van Amelsvoort15, Celso Arango16, Tilo Kircher17, Barnaby Nelson18,19, Silvana Galderisi20, Rodrigo Bressan21, Jun S. Kwon22, Mark Weiser23,24, Romina Mizrahi25–27, Gabriele Sachs28, Anke Maatz29, René Kahn30, and Phillip McGuire1,2,5; the PSYSCAN Consortium**

1Department of Psychiatry Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 2Outreach and Support in South London (OASIS), South London and Maudsley NHS Foundation Trust, London, UK; 3Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht, the Netherlands; 4Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; 5National Institute for Health Research, Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK; 6Department Early Psychosis, Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; 7CIBERSAM, Department of Psychiatry, University Hospital Virgen del Rocío, Sevilla, Spain; 8IDIVAL, Marqués de Valdecilla University Hospital, Santander, Spain; 9School of Medicine, University of Cantabria, Santander, Spain; 10Centre for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark; 11Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark; 12Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK; 13Centre for Neuroimaging & Cognitive Genomics (NICOG), NCBS Galway Neuroscience Centre, National University of Ireland Galway, Galway, Ireland; 14Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Germany; 15Department of Psychiatry and Neurology, Maastricht University, Maastricht, The Netherlands; 16Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañon, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain; 17Department of Psychiatry, University of Marburg, Marburg, Germany; 18Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; 19Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia; 20Department of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy; 21Interdisciplinary Lab for Clinical Neurosciences (LiNC), Department of Psychiatry, Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil; 22Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea; 23Department of Psychiatry, Sheba Medical Center, Tel Hashomer, Israel; 24Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; 25Institute of Medical Science, University of Toronto, Toronto, Canada; 26Centre for Addiction and Mental Health, Toronto, Canada; 27Department of Psychiatry, University of Toronto, Toronto, Canada; 28Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; 29Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland; 30Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY

†These authors contributed equally to this work.

*To whom correspondence should be addressed; Clinical Trial Center, Department of Psychiatry, University Medical Center Utrecht Brain Center, PO Box 85500, 3508 GA Utrecht, The Netherlands; tel: +31 88 755 7247, e-mail: h.h.vanhell-2@umcutrecht.nl

**Full list of authors can be found at the end of the article.

In the last 2 decades, several neuroimaging studies investigated brain abnormalities associated with the early stages of psychosis in the hope that these could aid the prediction of onset and clinical outcome. Despite advancements in the field, neuroimaging has yet to deliver. This is in part explained by the use of univariate analytical techniques, small samples and lack of statistical power, lack of external validation of potential biomarkers, and lack of integration of nonimaging measures (eg, genetic, clinical, cognitive data). PSYSCAN is an international, longitudinal, multicenter study on the early stages of psychosis which uses machine learning techniques to analyze imaging, clinical, cognitive, and biological data with the aim of facilitating the prediction of psychosis onset and outcome. In this article, we provide an overview of the PSYSCAN protocol and we discuss benefits and methodological challenges of large multicenter studies that employ neuroimaging measures.

Keywords: psychosis/first episode of psychosis/clinical high risk of psychosis/PSYSCAN/neuroimaging/MRI/machine learning/prediction

© The Author(s) 2019. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Neuroimaging provides a powerful, noninvasive method to unveil some of the neurobiological mechanisms underlying serious psychiatric disorders such as schizophrenia. In the last 2 decades, researchers have tried to identify brain abnormalities that could aid the prediction of psychosis onset\textsuperscript{1-5} and clinical outcomes\textsuperscript{6-12} in the early stages of psychosis, so that patients can be offered different forms of treatment according to their individual needs. For example, despite several advancements, one of the key challenges in the management of individuals at clinical high risk of psychosis (CHR-P) is that it is not currently possible to identify the subgroups that will subsequently transition to psychosis or that will develop other mental health disorders\textsuperscript{13,14}. Stratification of these subgroups would allow potentially preventative interventions to be selectively offered to these individuals.\textsuperscript{15,16} This is an important task given that one-size-fits-all therapeutic approaches are not particularly effective in about one-third of patients\textsuperscript{17,18}. It is currently not possible to predict if and when patients will suffer a relapse solely on clinical presentation. If course of illness could be determined early on, targeted intervention could potentially prevent future hospitalizations. Another important challenge in the management and treatment of people with psychosis is that available antipsychotic medications are partially or not effective in about one-third of patients.\textsuperscript{17,18}

Precision medicine in psychosis involves early detection and intervention services involved, inter-site differences in catchment area populations, type of mental health to make predictions on a number of neurological and psychiatric conditions, including Alzheimer,\textsuperscript{16} depression,\textsuperscript{17,18} anxiety disorders,\textsuperscript{19} eating disorders,\textsuperscript{20} and psychosis\textsuperscript{6,10,33,41,42}. In this context, clinically valid and reliable neuroimaging biomarkers of psychosis onset and outcome have yet to be identified, as the results from structural, functional, and neurochemical magnetic resonance imaging (MRI) studies are mixed. This might in part be explained by (1) differences in the sociodemographic (eg, age, ethnicity, migration, socioeconomic status) and clinical features of the samples studied, which often reflect inter-site differences in catchment area populations, type of early detection and intervention services involved, and potential sampling biases (particularly in CHR-P individuals\textsuperscript{25}); (2) the use of relatively small samples, which might result in type I and type II errors\textsuperscript{26} and therefore limited generalizability of the findings; (3) heterogeneous image preprocessing protocols; and lastly (4) the use of different inclusion criteria in different studies, leading to substantial heterogeneity in symptom severity and comorbidities.

To date, the majority of neuroimaging studies investigating abnormalities in the CHR-P and FEP populations have employed univariate analytical methods that allow statistical inferences at the group, rather than the individual level. Although univariate approaches are suited to detect focal abnormalities at a group level, differences in brain anatomy and functioning in the early stages of psychosis appear to be relatively subtle and widespread.\textsuperscript{5,27-29} Univariate approaches also involve multiple testing and the subsequent correction for multiple comparisons, which may be too conservative and not sensitive enough to detect alterations that are expressed at a network level rather than in a few distinct brain areas. The application of multivariate data-driven approaches, such as machine learning\textsuperscript{30,31} allows inferences to be made at the individual level, and therefore carry greater translational potential for application in clinical practice.\textsuperscript{32,33}

Machine learning has been employed in the field of mental health to make predictions on a number of neurological and psychiatric conditions, including Alzheimer,\textsuperscript{36} depression,\textsuperscript{37,38} anxiety disorders,\textsuperscript{39} eating disorders,\textsuperscript{40} and psychosis\textsuperscript{6,10,33,41,42} (for critical reviews, please see Orrù et al,\textsuperscript{30} Gifford et al,\textsuperscript{22} Vieira et al\textsuperscript{31} Arbabshirani et al\textsuperscript{23} and Dwyer et al\textsuperscript{45}). In the context of psychosis, machine learning has been used to investigate different stages of illness ranging from psychosis risk,\textsuperscript{10,41,44} first episode of psychosis\textsuperscript{6,43}, to established schizophrenia.\textsuperscript{46} Studies have employed structural\textsuperscript{44} and functional MRI data\textsuperscript{47} but also nonimaging data\textsuperscript{41} to make predictions on broadly 3 areas: diagnosis, prognosis, and response to treatment. Aiding diagnosis classification is clinically helpful for some psychiatric conditions, such as anxiety disorders, or prodromal stages, where there is diagnostic uncertainty,\textsuperscript{36,44} while for other conditions, such as established schizophrenia, prediction of prognosis or response to treatment might be clinically more meaningful.\textsuperscript{6,33}

Studies on the early stages of psychosis, including both FEP and CHR-P individuals have generally shown accuracies above 75%\textsuperscript{23,30,43} However, a recent study challenged the potential of machine learning for detecting changes in the early stages of psychosis. Using relatively large datasets of FEP patients, Vieira et al\textsuperscript{45} reported lower classification accuracies than previous studies (between 50% and 70%), but also poor generalizability of models to other sites.\textsuperscript{45} While the initial machine learning studies suggest that this approach holds some promise, they have involved relatively small groups
This is important as the reliability of machine learning is directly affected by sample size, and overall accuracies are seen to decrease with sample size. This also suggests that results from previous studies, including studies on patients with psychosis, may not be generalizable, and so must be interpreted with caution. This also suggests that overfitting may be taking place; which is when a machine learning model is fitted to noise in the data rather than to an underlying pattern of interest. In this context, overfit models might give very high accuracies on the training data but will not generalize to new data. On the other hand, a negative correlation between sample size and accuracy might also be a sign of publication bias rather than overfitting. A further limitation of multivariate studies in the field to date is that in most cases, the findings have not been validated in an independent dataset. Finally, each lab tends to use its own pre-processing techniques and machine learning analytical approaches, adding further complexity/heterogeneity when comparing results from different studies.

Structural and functional brain changes are not the only objective measures that can be used to aid prediction of clinical outcome in psychosis. Indeed, evidence suggests that psychosis is associated with genetic changes as well as alterations in cognitive functioning. Therefore, integrating neuroimaging, biological, clinical, and cognitive data may facilitate the multimodal prediction of psychosis onset and clinical outcomes. In this context, multivariate analysis approaches such as machine learning, which can take into account simultaneously different clinically meaningful measures, have the potential of generating valid, clinically relevant, and usable prediction models.

PSYSCAN (http://psyscan.eu) is a research program funded as part of the European Funding 7th Framework Programme that was designed to address the methodological issues described above, with the goal of translating findings from neuroimaging, genetics, clinical and cognitive measures from individuals in the early phase of psychosis (ie, CHR-P and FEP) into mainstream clinical practice.

PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice

PSYSCAN is an international, longitudinal, multicenter study on the early stages of psychosis (ie, CHR-P and FEP stages) involving partners from the United Kingdom (London and Edinburgh), the Netherlands (Amsterdam, Maarstricht, and Utrecht), Spain (Madrid and Santander), Denmark (Glostrup/Copenhagen), Germany (Marburg and Heidelberg), Ireland (Galway), Israel (Tel Aviv), Austria (Vienna), Switzerland (Zurich), Australia (Melbourne), Italy (Naples), plus affiliate sites in China (Hong Kong), Canada (Toronto), South Korea (Seoul), and Brazil (Sao Paulo). This consortium aims to recruit a large sample of CHR-P and FEP participants and to collect a number of multimodal imaging measures (ie, structural, resting state functional MRI, and diffusion tensor imaging data), which will be integrated with psychopathological, sociodemographic, genetic, metabolomic, proteomic, immunological and cognitive data with the aim of improving outcome prediction. Data are being collected at first presentation and again at a number of follow-up timepoints, with the same instruments and methodological procedures being used at each site. A healthy control group is also being recruited and will serve as a comparative/control group for the CHR-P as well as for the FEP cohort.

Figure 1 and table 1 show the design of the PSYSCAN study. Supplementary material 1 provides a detailed overview of the sociodemographic information, clinical, and cognitive measures collected at the different follow-up timepoints.

Methodological Considerations in Multimodal Multicenter Studies

Multicenter studies provide a means of acquiring data from relatively large samples of subjects, representing different geographical areas. However, the involvement of several sites also introduces methodological challenges, particularly in controlling for the effects of site differences when acquiring imaging data. Table 2 lists some potential benefits and challenges that can arise when performing multicenter studies involving imaging acquisition.

Use of a Common Imaging Acquisition Protocol Across Sites

One of the major issues in multicenter neuroimaging studies is the effects of intersite variations in scanner make, model, and field strength. To minimize such effects, all sites in the PSYSCAN consortium used 3T scanners, adopted a common image acquisition protocol and underwent a site qualification procedure to ensure that the standard acquisition protocol could be implemented locally (supplementary materials 2). The site qualification was led by IXICO (https://ixico.com), the industrial partner in this project. The acquisition protocol includes published pulse-sequence design (ie, Alzheimer’s Disease Neuroimaging Initiative ADNI-2 T1 and ADNI-3 FLAIR) and study-specific Diffusion Tensor Imaging (DTI) and resting state functional MRI sequences (supplementary materials 2).

Healthy Traveling Subjects Scanned at Different Sites

In the PSYSCAN study, although all sites are using scanners with the same field strength and harmonized acquisition parameters (supplementary materials 2), additional variability can still arise through the use of scanners that differ in model, manufacturer or specific features. The study has therefore included a travelling...
subject study, an approach that has been previously adopted in other multicenter studies.\textsuperscript{65,66} Six healthy individuals have been scanned on 2 separate occasions using the PSYSCAN neuroimaging protocol, at 6 sites within the consortium. The data from these subjects will be used to quantify within- and between-scanner heterogeneity, to identify the determinants of this variance, to quantify the effects on the data, and to develop post-hoc calibration methods to attenuate these effects.

Recruitment at Different Sites

A further methodological challenge for multicenter studies is to ensure reliability of nonimaging data collection across multiple sites. Work-Package 5 (WP5) is responsible for collecting data from (1) CHR-P individuals, (2) FEP patients, and (3) healthy controls, in a naturalistic prospective design. Standardized and harmonized psychopathological, demographic, cognitive, and genetic measures are collected at baseline and during follow-up assessments. Researchers at each site completed both face-to-face and online training (http://psyscan.eu) on the instruments being used to screen and assess participants, including, but not limited to, the Positive and Negative Syndrome Scale,\textsuperscript{67} a revised version of the Comprehensive Assessment of an At Risk Mental State\textsuperscript{68} which allows the additional scoring of the Structured Interview of Psychosis-Risk Syndromes\textsuperscript{69} and the Schizophrenia Proneness Instrument for Adults.\textsuperscript{70} To further ensure reliability across sites, particularly in the assessment of CHR-P participants, teleconferences to discuss all included cases take place every 1–2 months. Centralized monitoring and yearly on-site monitoring visits are also conducted to ensure that the protocols are being followed correctly, and to address any local issues related to subject assessment and follow-up. Cognitive function is assessed on iPads using tests derived from the CANTAB cognitive battery\textsuperscript{71} (ie paired associates learning, spatial span task, processing speed, emotion recognition task). These are brief computerized tests which participants perform using an iPad, with a total assessment time of around 20 minutes. Twenty minutes was chosen as a feasible time frame for clinical practice. The use of nonverbal rather than verbal tasks facilitates the use of the assessment in subjects with a wide range of native languages. Using a computerized assessment permits vocal instructions in the subject’s native language to be embedded within the test (translation was done from English to the 10 other languages part of the consortium using a forward/backward translation method, and a check of the vocal instructions by a native speaker).\textsuperscript{71}
Table 1. Aims and Expected Outcomes From PSYSCAN Work-Packages (WP)

| Work-Package | Aim | Outcome |
|--------------|-----|---------|
| WP1. Management of the PSYSCAN project | To ensure (a) scientific dialogue and communication across the consortium and (b) efficient administration and reporting in accordance with EC guidelines and requirements | Overall organization and coordination of the PSYSCAN project and consortium |
| WP2. Merged legacy datasets | To collect, organize, analyze, and report on existing datasets collected by the consortium partners over the last 20 years from (a) patients with psychosis, (b) patients with genetic vulnerability for psychosis (22q1.2 deletion syndrome), (c) subjects at clinical high risk of psychosis (CHR-P), and (d) healthy controls | Development of new methods Data analysis on merged existing datasets New methods testing and validation |
| WP3. Development of software for data analysis | To design, code, assemble, document, and test new specialized software modules for machine learning, connectivity and network analysis | Development of new methods for the analysis or imaging, clinical, cognitive, and biological data Application of machine learning techniques on legacy and prospective data |
| WP4. Data management | Responsible for (a) the technical aspects of data management of both WP2 and WP5, (b) development of quality control protocols for imaging data collected as part of WP5 | Large database with neuroimaging, demographic, cognitive and clinical data collected as part of WP5 |
| WP5. Naturalistic prospective study | To collect new, homogenized data from (a) CHR-P individuals, (b) patients with first episode psychosis (FEP), and (c) healthy controls in a naturalistic prospective study comprising around 1000 subjects in total. Standardized and harmonized measures of neuroimaging, clinical, cognitive, biological, and genetic variables are collected at baseline and at follow-up to determine clinical and functional outcomes. | New longitudinal neuroimaging, cognitive, clinical, and biological measures collected from ~700 subjects (CHR-P, FEP, and HC) |
| WP6. Dissemination | To disseminate the activities and results of PSYSCAN, including the development of a website (psyscan.eu), annual stakeholder workshops for consultation and dissemination, production of leaflets, social media engagement (including Facebook and Twitter), publication of articles in scientific journals, and the organization of a final PSYSCAN conference | PSYSCAN website, publications, workshops, and conference |

Table 2. Methodological Considerations in Multicenter Studies Involving Neuroimaging

| Benefits | Challenges |
|----------|------------|
| Use of a common imaging acquisition protocol across sites | Site qualification is resource intensive and time consuming Site qualification is resource intensive and time consuming Site qualification is resource intensive and time consuming |
| Recruitment at different sites | Standardized and on-going quality check to ensure that there are no changes to the MRI protocol is resource intensive and time consuming Compromise on acquisition protocols used, as not all sites have access to latest technology |
| Healthy traveling subjects scanned at different sites | Logistically and resource intensive Under-recruitment at single sites can be problematic in future analyses, particularly for neuroimaging analyses |
| Use of legacy data | Due to the small group, generalizability can be questionable |
| Combining imaging and nonimaging data | Logistically intensive, potentially expensive Jet lag can influence state of alertness and affect functional MRI |

436
Use of Legacy Data

In addition to the new data being acquired in WP5, existing data from previous studies have been collated from more than 3000 subjects, using 16 datasets from 9 of the consortium partners. These include structural MRI, DTI, and fMRI data, as well as nonimaging data (basic sociodemographic and clinical data), from patients with psychosis, patients with genetic vulnerability for psychosis (22q11.2 deletion syndrome), CHR-P individuals and healthy controls. These legacy data are being used to facilitate the development of novel machine learning algorithms that will be applied to the new datasets from WP5. These algorithms will initially be validated by dividing the samples into discovery and validation subsamples, and more definitively by testing the algorithms on analogous, independent datasets from other research consortia, through the Harmonization of At Risk Multisite Observational Networks for Youth (HARMONY) collaboration that includes the Personalised Prognostic Tool for early Psychosis Management (PRONIA—another EU-FP7 program) and 2 National Institute of Mental Health (NIMH)—funded programs, the North American Prodrome Longitudinal Study (NAPLS), and the Philadelphia Neurodevelopmental Cohort (PNC).

Combining Imaging and Nonimaging Data

One of the core aims of the project is to integrate neuroimaging, clinical, cognitive, and peripheral biomarker data to facilitate the prediction of psychosis onset, clinical and functional outcomes. Therefore, alongside clinical and cognitive data, blood samples (including whole blood, serum, and plasma) are collected for analyses of genomic, proteomic, metabolomic, and immune markers at baseline, 6 and 12 months in the CHR-P and HC cohorts and at baseline and 12 months in the FEP cohort. In particular, DNA will be extracted from whole blood for a GWAS analysis to allow the polygenic risk score for schizophrenia to be determined for each individual. A broad range of proteomic and metabolomic and immunological markers will be examined which can be readily determined from the frozen serum and plasma samples. Current markers in the literature have highlighted CFI and C6 proteins, reduced levels of essential polyunsaturated fatty acids and increased levels of IL-6, however, this is a rapidly developing field so we will plan to undertake both an exploratory and hypothesis-led approach based on the most recent findings at the time of analysis.

To date, most predictive algorithms in psychosis have used data from a single modality, such as MRI data or clinical data. The combination of imaging and nonimaging data may result in a more accurate model with higher predictive power compared with that of previous prediction tools. In particular, if different risk estimation tools are used in the context of a sequential and stepped assessment to enrich the risk prediction. With both legacy and newly collected data, supervised machine learning approaches will be used to predict clinically meaningful outcomes (eg, psychosis onset, social and role functioning, changes in symptom scores, and treatment response) from both neuroimaging and nonneuroimaging data. Similarly, unsupervised machine learning approaches will be used to identify subgroups of patients and investigate their clinical outcomes. These subgroups could potentially then be used to further inform supervised learning, for instance, by stratifying the subjects before making predictions.

Future Directions

Key steps for future progress in the field include the validation of prognostic and predictive algorithms in independent datasets from other projects (ie, external validation). Wide collaborations with other consortia such as HARMONY will provide the opportunity to initiate such endeavours. This independent validation of prognostic/predictive algorithms is critical to the ultimate identification of measures that can reliably predict psychosis onset in CHR-P individuals or clinical outcomes in those with a first episode of psychosis. For these measures to be embedded in day-to-day clinical practice they ideally should be collectable using methods that (1) are widely available, (2) do not require an excessive amount of patient or clinician time, and that (3) have a reasonable cost. This applies to some of the potentially useful measures in psychosis, such as MRI scanning or a blood sample for whole genome sequencing, whereas others may require technology that is relatively inaccessible (eg, positron emission tomography—PET-scanning) or analyses that are currently relatively expensive (eg, proteomics). It is therefore more likely that complex, multimodal, risk estimation algorithms would enter clinical routine only in a stepped risk assessment framework, in line with previous successful examples of clinical medicine (eg, cardiovascular and pulmonary).

Overall, PSYSCAN and similar large cohort studies are purposely designed to significantly contribute to the bench-to-bed approach and aim to develop clinically usable tools to predict psychotic illness onset and course, differential diagnosis, treatment response, and functional outcome, with practical implications for individualized treatment.

Supplementary Material

Supplementary data are available at Schizophrenia Bulletin online.

Funding

The PSYSCAN Project is supported by grant agreement no. 603196 under the European Union’s Seventh Framework Programme.
Acknowledgments

We would like to thank all participants who took part in the study. Conflict of Interest: S.G. received honoraria, advisory board, or consulting fees from the following companies: Gedeon-Richter, Janssen Pharmaceuticals, Janssen-Cilag Polska Sp. z o.o, Otsuka, Pierre Fabre and Sunovion Pharmaceutica. B.G. is the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), which is partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. Her group has also received a research grant from Lundbeck A/S for another independent investigator initiated study. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administered by them. G.S. is president of the Austrian Society of Neuropsychopharmacology and Biological Psychiatry, which is partially financed by the support from pharmaceutical companies. G.S. received consulting fees and/or honoraria for speeches within the last 3 years from Angelini, AOP Orphan, Alkermes, Janssen, Lundbeck, Pfizer. PFP received advisory board fees and research funds from Lundbeck.

References

1. Mechelli A, Riecher-Rössler A, Meisenzahl EM, et al. Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch Gen Psychiatry. 2011;68(5):489–495.
2. Pantelis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003;361(9354):281–288.
3. Tognin S, Riecher-Rössler A, Meisenzahl EM, et al. Reduced parahippocampal cortical thickness in subjects at ultra-high risk for psychosis. Psychol Med. 2014;44(3):489–498.
4. Koutsouleris N, Riecher-Rossler A, Meisenzahl EM, et al. Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers. Schizophr Bull. 2015;41(2):471–482.
5. Smieskova R, Fusar-Poli P, Allen P, et al. Neuroimaging predictors of transition to psychosis—a systematic review and meta-analysis. Neurosci Biobehav Rev. 2010;34(8):1207–1222.
6. Koutsouleris N, Kahn RS, Chekroud AM, et al. Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. Lancet Psychiatry. 2016;3(10):935–946.
7. de Wit S, Ziemans TB, Nieuwenhuis M, et al. Individual prediction of long-term outcome in adolescents at ultra-high risk for psychosis: applying machine learning techniques to brain imaging data. Hum Brain Mapp. 2017;38(2):704–714.
8. Nieuwenhuis M, Schnack HG, van Haren NE, et al. Multicenter MRI prediction models: predicting sex and illness course in first episode psychosis patients. Neuroimage. 2017;145(Pt B):246–253.
9. Amminger GP, Mechelli A, Rice S, et al. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. Transl Psychiatry. 2015;5:e495.
10. Tognin S, Pettersson-Yeo W, Valli I, et al. Using structural neuroimaging to make quantitative predictions of symptom progression in individuals at ultra-high risk for psychosis. Front Psychiatry. 2013;4:187.
11. Egerton A, Broberg BV, Van Haren N, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE). Mol Psychiatry. 2018;23(11):2145–2155.
12. Bossong MG, Antoniades M, Azis M, et al. Association of hippocampal glutamate levels with adverse outcomes in individuals at clinical high risk for psychosis. JAMA Psychiatry. 2018.
13. Fusar-Poli P, Cappucciati M, Bonoldi I, et al. Prognosis of brief psychotic episodes: a meta-analysis. JAMA Psychiatry. 2016;73(3):211–220.
14. Fusar-Poli P, Cappucciati M, Borgwardt S, et al. Heterogeneity of psychosis risk within individuals at clinical high risk: a meta-analytical stratification. JAMA Psychiatry. 2016;73(2):113–120.
15. Davies C, Radua J, Cipriani A, et al. Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis. Front Psychiatry. 2018;9:187.
16. Davies C, Cipriani A, Ioannidis JPA, et al. Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. World Psychiatry. 2018;17(2):196–209.
17. Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303–318.
18. Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927–942.
19. Butcher NJ, Fung WL, Fitzpatrick L, et al. Response to clozapine in a clinically identifiable subtype of schizophrenia. Br J Psychiatry. 2015;206(6):484–491.
20. Morrison AP, Pyle M, Gumley A, et al.; FOCUS trial group. Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. Lancet Psychiatry. 2018;5(8):633–643.
21. Schooler NR. Cognitive behavioural therapy for clozapine non-responders. Lancet Psychiatry. 2018;5(8):607–608.
22. Gifford G, Crossley N, Fusar-Poli P, et al. Using neuroimaging to help predict the onset of psychosis. Neuroimage. 2017;145(Pt B):209–217.
23. Arbabshirani MR, Plis S, Sui J, Calhoun VD. Single subject prediction of brain disorders in neuroimaging: Promises and pitfalls. Neuroimage. 2017;145(Pt B):137–165.
24. Jansen RJ, Mourao-Miranda J, Schnack HG. Making individual prognoses in psychiatry using neuroimaging and machine learning. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3(9):798–808.
25. Fusar-Poli P, Schulze-Lutter F, Cappucciati M, et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull. 2016;42(3):732–743.
26. Button KS, Ioannidis JP, Mokrysz C, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14(5):365–376.
60. Jovicich J, Czanner S, Han X, et al. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. *Neuroimage*. 2009;46(1):177–192.

61. Krugell F, Turner J, Multutler LT; Alzheimer’s Disease Neuroimaging Initiative. Impact of scanner hardware and imaging protocol on image quality and compartment volume precision in the ADNI cohort. *Neuroimage*. 2010;49(3):2123–2133.

62. Vogelbacher C, Möbius TWD, Sommer J, et al. The Marburg-Münster Affective Disorders Cohort Study (MACS): a quality assurance protocol for MR neuroimaging data. *Neuroimage*. 2018;172:450–460.

63. Reig S, Sánchez-González J, Arango C, et al. Assessment of the increase in variability when combining volumetric data from different scanners. *Hum Brain Mapp*. 2010;30(2):355–368.

64. Initiative AsDN. ADNI | MRI acquisition—Alzheimer’s disease neuroimaging initiative. http://adni.loni.usc.edu/methods/mri-tool/mri-acquisition/.

65. Schnack HG, van Haren NE, Brouwer RM, et al. Mapping cortical thickness. *Hum Brain Mapp*. 2010;31(12):1967–1982.

66. Cannon TD, Sun F, McEwen SJ, et al. Reliability of neuroanatomical measurements in a multisite longitudinal study of youth at risk for psychosis. *Hum Brain Mapp*. 2014;35(5):2424–2434.

67. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13(2):261–276.

68. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. *Aust N Z J Psychiatry*. 2005;39(11–12):964–971.

69. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. *Schizophr Bull*. 2003;29(4):703–715.

70. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. *Schizophr Bull*. 2003;29(4):703–715.

71. Barnett JH, Robbins TW, Leeson VC, Sahakian BJ, Joyce EM, Blackwell AD. Assessing cognitive function in clinical trials of schizophrenia. *Neurosci Biobehav Rev*. 2010;34(8):1161–1177.

72. Focking M, Pollak T, Dicker P, et al. Proteomic analysis of complement pathway protein changes. *Neurosci Biobehav Rev*. 2018;44(2):326–336.

73. Davison J, O’Gorman A, Brennan L, Cotter DR. A systematic review of metabolite biomarkers of schizophrenia. *Schizophr Res*. 2018;195:32–50.

74. Orlowska-Waast S, Kohler-Forsberg O, Brix SW, et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. *Mol Psychiatry*. 2018;24(6):869–887.

75. Dazzan P, Arango C, Fleischacker W, et al. Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research. *Schizophr Bull*. 2015;41(3):574–583.

76. Cannon TD, Yu C, Addington J, et al. An individualized risk calculator for research in prodromal psychosis. *Am J Psychiatry*. 2016;173(10):980–988.

77. Schmidt A, Cappucciat M, Radua J, et al. Improving prognostic accuracy in subjects at clinical high risk for psychosis: systematic review of predictive models and meta-analytical sequential testing simulation. *Schizophr Bull*. 2017;43(2):375–388.

78. Dwyer DB, Cabral C, Kambet-Lankovic L, et al. Brain subtyping enhances the neuroanatomical discrimination of schizophrenia. *Schizophr Bull*. 2018;44(5):1060–1069.

The PSYCAN Consortium

Philip McGuire1,2, Stefania Tognin1, Paolo Fusar-Poli1,2, Matthew Kempton1,2, Gemma Modinos1, Kate Merritt1, Andrea Mechelli1, Paola Dazzan1, George Gifford2, Natalia Petros3, Mathilde Antoniades4, Andrea De Micheli4, Sandra Vieira5, Tom J Spencer6, Cristina Scarpazza1, Emily Hird7, Rene Kahn4,8, Arija Maat9, Erika van Heil10, Inge Winter10, Wiepke Cahn10, Hugo Schnack10, Lievee de Han11, Diewoue Siegmann10, Jana Barkhof12, Lotte Hendriks13, Iris de Wit14, Benedito Crespo-Facorro15, Diana Torresdel-Gutierrez1, Esther Setien-Suero16, Rosa Ayesa-Arriola17, Paula Suarez-Pinilla17, Maria Luz Ramirez-Bonilla17, Victor Ortiz Garcia-de la font1,28, Birte Genthoff29, Mikkel Erlang Sorensen30, Karen Tangmose10, Helle Schiebel10, Brian Broberg10, Egil Rostrup10,28, Stephen Lawrie10, Colm McDonald10, Brian Hallahan10, Dara Cannon10, James McLoaghtlin10, Martha Finnegan10, Oliver Gruber10, Therese van Ameloot10,11, Danny Deckers10,11, Machteld Marcelis10,11, Claudia Vingerhoets10,11, Celso Arango16, Covadonga M. Diaz-Caneja16, Miriam Ayora16, Joost Janssen16, Roberto Rodriguez-Jimenez16, Marina Diaz-Marsà16, Tilo Kircher16, Irina Falkenberg16, Florian Bitsch16, Philipp Berger16, Jens Sommer19,28, Kyeon Raab19, Babette Jakobi19, Barnaby Nelson19,22, Patrick McGorry21,22, Paul Amminger21,22, Meredith McHugh21,22, Silvana Gallideris23, Armida Mucci23, Paola Buccion23, Giuseppe Piegar23, Daria Pietrafesa23, Alessia Nicita23, Sara Patrirta23, Rodrigo Bressan24, André Zugman24, Ary Gadelha24, Gracielle Rodrigues da Cunha24, Jun Soo Kwon24, Kang Ik Kevin Cho24, Tae Young Lee25, Minah Kim25, Yoo Bin Kwak25, Wu Jeong Hwang25, Mark Weiser25, Romina Mizrahi27,28,29, Michael Kiang27,28,29, Cory Gerritsen28,29, Margrét Maheandiran28, Sarah Ahmed27,28, Ivana Pecce28, Jenny Lepock28,29, Gabriele Sachs29, Matthiaus Willeit28,29, Marzena Lenczowski28,35, Ullrich Sauerzopf28,35, Ana Weidenauer29, Julia Furtner-Srayer29, Matthias Kirschner29,30, Anke Maat29,30, Achim Burrer29,30, Philipp Stämpfli29,30, Naemi Huber29, Stefan Kaiser34,35, Wolfram Kavoii30, Michael Brammer30, Jonathan Young30,1, Edward Bullmore30,31, and Sarah Morgan30,31.

Affiliations

1. Department of Psychiatry Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK

2. National Institute for Health Research, Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK

3. University Medical Center, Division of Neurosciences, Department of Psychiatry, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

4. Department of Psychiatry and Behavioral Health System, Institute of Psychiatry, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

5. CIBERSAM, Department of Psychiatry, University Hospital Virgen del Rocio, Sevilla; Marqués de Valdecilla University
Hospital, IDIVAL. School of Medicine, University of Cantabria, Santander, Spain
7. CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Spain
8. Centre for Neuropsychiatric Schizophrenia Research (CNSR) & Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark
9. University of Copenhagen, Faculty of Health and Medical Sciences, Dept. of Clinical Medicine, Copenhagen, Denmark
10. Functional Imaging Unit (FIUNIT), Rigshospitalet Glostrup, University of Copenhagen, Glostrup, Denmark
11. Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh EH10 5HF, UK
12. Centre for Neuroimaging & Cognitive Genomics (NICOG), NCBES Galway Neuroscience Centre, National University of Ireland Galway, H91 TK33 Galway, Ireland
13. Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Germany
14. Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands
15. GGZ&E Mental Health Care, Eindhoven, the Netherlands
16. Servicio de Psiquiatría del Niño y del Adolescente, Hospital General Universitario Gregorio Marañón, Universidad Complutense Madrid, Spain; Centro de Investigación Biomédica en Red de Salud Mental, Madrid, Spain
17. Departamento de Psiquiatría, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; CIBERSAM (Biomedical Research Networking Centre in Mental Health), Spain
18. Hospital Clínico de San Carlos, Universidad Complutense, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, España
19. Dept of Psychiatry, University of Marburg, Rudolf-Bultmann-Straße 8, D-35039, Marburg, Germany
20. Core-Facility Brainimaging, Faculty of Medicine, University of Marburg
21. Orygen, The National Centre of Excellence in Youth Mental Health, 35 Poplar Road, Parkville, Victoria, Melbourne, Australia
22. Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia
23. Department of Psychiatry, University of Campania Luigi Vanvitelli, Largo Madonna delle Grazie, 80138, Naples, Italy
24. Department of Psychiatry, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil
25. Department of Psychiatry, Seoul National University College of Medicine, 101 Dahakno, Jongno-gu, Seoul, Korea
26. Department of Psychiatry, Sheba Medical Center, Tel Hashomer 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
27. Institute of Medical Science, University of Toronto, 1 King’s College Circle Room 2374, Toronto, Ontario, Canada M5S 1A8
28. Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
29. Department of Psychiatry, University of Toronto, 250 College Street 8th Floor, Toronto, Ontario, Canada M5T 1R8
30. Department of Psychology, University of Toronto, 100 St. George Street 4th Floor, Toronto, Ontario, Canada M5S 3G3
31. Department of Psychiatry and Psychotherapy, 1090 Vienna, Austria
32. Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy Währingerürtel 18–20, 1090 Vienna
33. Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Switzerland
34. Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
35. Clinical and Experimental Psychopathology Laboratory, Faculty of Medicine, University of Geneva, Switzerland
36. Adult Psychiatry Division, Department of mental health and psychiatry, University Hospitals of Geneva, Switzerland
37. Department for Psychiatry and Psychotherapy, Psychiatric Services Aargau, Brugg, Switzerland
38. Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
39. IXICO plc, London, UK
40. Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK